IDXG

Interpace Biosciences Inc

IDXG, USA

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

https://www.interpace.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IDXG
stock
IDXG

Interpace Biosciences (OTCID: IDXG) clears BroadOak loan, eliminating interest expense Stock Titan

Read more →
IDXG
stock
IDXG

Interpace Biosciences Repays Loan Early for Growth TipRanks

Read more →

Showing 2 of 8

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$11

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-17.30

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-305.70 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

High

7.57 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

20.80 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 3.72% of the total shares of Interpace Biosciences Inc

1.

BlackRock Inc

(2.8485%)

since

2020/12/31

2.

Geode Capital Management, LLC

(0.7896%)

since

2020/12/31

3.

Tower Research Capital LLC

(0.0469%)

since

2020/12/31

4.

Retirement Group, LLC

(0.0243%)

since

2021/03/31

5.

USAA Extended Market Index

(0.012%)

since

2021/03/31

6.

Advisor Group Holdings, Inc.

(0.0012%)

since

2020/12/31

7.

Wells Fargo & Co

(0.0006%)

since

2020/12/31

8.

NT Quality Small Cap Core

(0.0005%)

since

2021/03/31

9.

NT Quality SCC US Fund - L

(0.0005%)

since

2021/03/31

10.

Morgan Stanley - Brokerage Accounts

(0.0001%)

since

2020/12/31

11.

Hanson Mcclain Inc

(0%)

since

2021/03/31

12.

Dimensional Fund Advisors, Inc.

(0%)

since

2021/03/31

13.

UBS Group AG

(0%)

since

2021/03/31

14.

Citadel Advisors Llc

(0%)

since

2020/12/31

15.

Magnus Financial Group LLC

(0%)

since

2020/12/31

16.

Penbrook Management LLC

(0%)

since

2020/12/31

17.

Stonepine Capital Management Llc

(0%)

since

2020/12/31

18.

Vanguard Group Inc

(0%)

since

2021/03/31

19.

Glenmede Trust Co NA

(0%)

since

2020/12/31

20.

Squarepoint Ops LLC

(0%)

since

2021/03/31

21.

NT Quality SCC Global Fund - NL

(0%)

since

2020/12/31

22.

NT Quality SCC US Fund - NL

(0%)

since

2020/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.